全文获取类型
收费全文 | 1024篇 |
免费 | 60篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 70篇 |
妇产科学 | 3篇 |
基础医学 | 127篇 |
口腔科学 | 30篇 |
临床医学 | 140篇 |
内科学 | 164篇 |
皮肤病学 | 24篇 |
神经病学 | 35篇 |
特种医学 | 186篇 |
外科学 | 63篇 |
综合类 | 28篇 |
预防医学 | 55篇 |
眼科学 | 16篇 |
药学 | 47篇 |
中国医学 | 1篇 |
肿瘤学 | 123篇 |
出版年
2023年 | 3篇 |
2022年 | 8篇 |
2021年 | 16篇 |
2020年 | 8篇 |
2019年 | 11篇 |
2018年 | 22篇 |
2017年 | 17篇 |
2016年 | 15篇 |
2015年 | 23篇 |
2014年 | 18篇 |
2013年 | 36篇 |
2012年 | 25篇 |
2011年 | 23篇 |
2010年 | 51篇 |
2009年 | 42篇 |
2008年 | 29篇 |
2007年 | 42篇 |
2006年 | 35篇 |
2005年 | 54篇 |
2004年 | 28篇 |
2003年 | 15篇 |
2002年 | 19篇 |
2001年 | 25篇 |
2000年 | 13篇 |
1999年 | 21篇 |
1998年 | 48篇 |
1997年 | 48篇 |
1996年 | 49篇 |
1995年 | 34篇 |
1994年 | 41篇 |
1993年 | 36篇 |
1992年 | 13篇 |
1991年 | 15篇 |
1990年 | 10篇 |
1989年 | 24篇 |
1988年 | 45篇 |
1987年 | 20篇 |
1986年 | 15篇 |
1985年 | 28篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 10篇 |
1978年 | 8篇 |
1977年 | 10篇 |
1976年 | 14篇 |
1975年 | 4篇 |
1973年 | 2篇 |
排序方式: 共有1119条查询结果,搜索用时 15 毫秒
31.
Effect of genetic modification of acute inflammatory responsiveness on tumorigenesis in the mouse 总被引:1,自引:3,他引:1
32.
33.
Theresa H M Keegan Sally L Glaser Christina A Clarke Margaret L Gulley Fiona E Craig Joseph A Digiuseppe Ronald F Dorfman Risa B Mann Richard F Ambinder 《Journal of clinical oncology》2005,23(30):7604-7613
PURPOSE: Epstein-Barr virus (EBV) in Hodgkin's lymphoma (HL) cells has been considered as a prognostic marker for this heterogeneous disease, but studies have yielded mixed findings, likely because of selected patient series and failure to acknowledge an effect of age on outcome. This study assessed survival after HL in a population-based cohort large enough to examine the joint effects of EBV with other factors including age, sex, and histologic subtype. PATIENTS AND METHODS: Included were 922 patients with classical HL diagnosed between mid-1988 and 1997 in the Greater San Francisco Bay Area, with archived biopsy specimens assayed for EBV with immunohistochemistry and in situ hybridization. Vital status was followed through December 30, 2003 (median follow-up time, 97 months). Overall and disease-specific survival were analyzed with the Kaplan-Meier method and Cox proportional hazards regression models. RESULTS: In children less than 15 years old, EBV presence was suggestively associated (P = .07) with favorable survival. In adults aged 15 to 44 years, EBV did not affect HL outcome, although a protective effect was suggested. In older adults (45 to 96 years), EBV presence nearly doubled the risk of overall and HL-specific mortality but only for patients with nodular sclerosis (NS) histologic subtype (hazard ratio for death = 2.5; 95% CI, 1.5 to 4.3). CONCLUSION: In HL, EBV tumor cell presence is associated with better survival in young patients and poorer survival in older patients with NS, independent of other factors. Variation in outcome by age and histology could indicate biologically distinct disease entities. Evidence that EBV is a meaningful prognostic marker may have therapeutic relevance. 相似文献
34.
Julia ML Brotherton 《Journal of paediatrics and child health》2014,50(12):959-965
The development of efficacious prophylactic human papillomavirus vaccines provided an opportunity for the primary prevention of related infections and diseases. Certain oncogenic human papillomaviruses that preferentially infect the genital epithelium cause cervical cancer and a substantial proportion of anal, penile, vaginal, vulvar and oropharyngeal cancers. Following extensive clinical trials demonstrating their efficacy and safety, two vaccines have been in global use for over 6 years. This review summarises the accumulated evidence regarding their high level of efficacy, safety in population usage, reductions in genital warts, infections and cervical disease following their adoption, and facilitators and barriers to achieving high vaccination coverage. The review also discusses practical issues and frequently asked questions regarding duration of effect, vaccination of women treated for cervical disease and alternate vaccination schedules, as well as the need to review cervical screening strategies in the post‐ vaccination environment. 相似文献
35.
36.
37.
38.
Elizabeth S. Gabitzsch Kwong Yok Tsang Claudia Palena Justin M. David Massimo Fantini Anna Kwilas Adrian E. Rice Yvette Latchman James W. Hodge James L. Gulley Ravi A. Madan Christopher R. Heery Joseph P. Balint Jr. Frank R. Jones Jeffrey Schlom 《Oncotarget》2015,6(31):31344-31359
Phenotypic heterogeneity of human carcinoma lesions, including heterogeneity in expression of tumor-associated antigens (TAAs), is a well-established phenomenon. Carcinoembryonic antigen (CEA), MUC1, and brachyury are diverse TAAs, each of which is expressed on a wide range of human tumors. We have previously reported on a novel adenovirus serotype 5 (Ad5) vector gene delivery platform (Ad5 [E1-, E2b-]) in which regions of the early 1 (E1), early 2 (E2b), and early 3 (E3) genes have been deleted. The unique deletions in this platform result in a dramatic decrease in late gene expression, leading to a marked reduction in host immune response to the vector. Ad5 [E1-, E2b-]-CEA vaccine (ETBX-011) has been employed in clinical studies as an active vaccine to induce immune responses to CEA in metastatic colorectal cancer patients. We report here the development of novel recombinant Ad5 [E1-, E2b-]-brachyury and-MUC1 vaccine constructs, each capable of activating antigen-specific human T cells in vitro and inducing antigen-specific CD4+ and CD8+ T cells in vaccinated mice. We also describe the use of a combination of the three vaccines (designated Tri-Ad5) of Ad5 [E1-, E2b-]-CEA, Ad5 [E1-, E2b-]-brachyury and Ad5 [E1-, E2b-]-MUC1, and demonstrate that there is minimal to no “antigenic competition” in in vitro studies of human dendritic cells, or in murine vaccination studies. The studies reported herein support the rationale for the application of Tri-Ad5 as a therapeutic modality to induce immune responses to a diverse range of human TAAs for potential clinical studies. 相似文献
39.
40.
Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease 总被引:5,自引:0,他引:5
Mannucci PM; Lattuada A; Castaman G; Lombardi R; Colibretti ML; Ciavarella N; Rodeghiero F 《Blood》1989,74(7):2433-2436
To characterize the heterogeneity of severe (type III) von Willebrand disease (vWD), plasma and platelet von Willebrand factor antigen (vWF:Ag) and ristocetin cofactor activity (Ricof) were measured in 28 obligatory heterozygotes (ie, parents or children of probands from 15 different kindreds with severe vWD). On the average, heterozygotes had low levels of vWF in both platelets and plasma. There was, however, considerable heterogeneity, with four distinct patterns. Eleven heterozygotes had concordant reduction of vWF:Ag and Ricof in both plasma and platelets; five had low levels of vWF:Ag and Ricof in plasma contrasting with normal levels in platelets; eight had a peculiar pattern, the reverse of the above (ie, low levels in platelets and normal levels in plasma); and in one, both vWF measurements were normal in plasma and platelets. These patterns were genetically determined: they were consistent in four couples of consanguineous heterozygotes and in two couples carrying the same gene deletion. Only the remaining three heterozygotes had no clearly identifiable pattern. Other findings of this study were that although most of the heterozygotes had normal bleeding times, the 7 of 28 who had prolonged bleeding times had concordantly low levels of vWF measurements in both plasma and platelets. In conclusion, this large series of obligatory heterozygotes provides evidence for phenotypic and genotypic heterogeneity of severe vWD. 相似文献